TSC22 domain family member 3Genealiases: DIP · DSIPI · GILZ · TSC-22R
Q-omics provides the consensus-scored TSC22D3 profile across patient tissues and cancer cell-line models. TSC22D3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TSC22D3 is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, TSC22D3 protein abundance shows 19,300 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight UVM, BLCA, and BRCA as cancer lineages where TSC22D3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TSC22D3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TSC22D3 survival associations across molecular data types. TSC22D3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TSC22D3 RNA expression–survival associations across cancer types. High TSC22D3 expression shows unfavorable associations in UVM and KIRP, but favorable associations in HNSC, LIHC, UCEC and CESC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TSC22D3 RNA expression.
This table summarizes TSC22D3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TSC22D3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TSC22D3 shows lower tumor expression in BLCA, COAD, KIRP, KICH and LUSC and higher tumor expression in KIRC. The BLCA box plot shows higher TSC22D3 RNA expression in normal versus tumor tissue (log2 FC = −2.080, t-test p < 0.001).
This table shows molecular features associated with TSC22D3 in patient tissues and cancer cell lines. In patient samples, TSC22D3 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, TSC22D3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LUNG_NSCLC_LUAD.
